BONESUPPORT HOLDING AB (SE:BONEX)
:BONEX
BONEX Stock Chart & Stats
kr184.80
-kr10.40(-2.96%)
At close: 4:00 PM EST
kr184.80
-kr10.40(-2.96%)
Day’s Range― - ―
52-Week Rangekr165.00 - kr346.40
Previous CloseN/A
Volume90.84K
Average Volume (3M)318.62K
Market Cap
kr14.11B
Enterprise Valuekr13.74B
Total Cash (Recent Filing)kr377.99M
Total Debt (Recent Filing)kr15.88M
Price to Earnings (P/E)87.1
Beta0.42
Next Earnings
Apr 22, 2026EPS Estimate
0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding65,859,190
10 Day Avg. Volume295,837
30 Day Avg. Volume318,624
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.72
Revenue Forecast (FY)kr1.50B
Bulls Say, Bears Say
Bulls Say
Exceptional Product Economics (gross Margins)Sustained gross margins near 90% indicate strong unit economics and pricing power for CERAMENT products. This durable advantage supports scalable profitability as volume grows, funds continued commercial and clinical investment, and provides a cushion versus modest cost or tariff pressures over the next 2–6 months.
Multi‑year Revenue Scale And U.S. Commercial TractionRapid multi‑year revenue expansion combined with deepening U.S. adoption (large CERAMENT G growth and distribution into >140 Level 1 trauma centers) shows durable market penetration. Broader account coverage and rising usage per account underpin sustained top‑line momentum and higher lifetime customer value.
Conservative Balance Sheet & Improved Cash GenerationVery low leverage and material positive free cash flow in 2024–2025 give the company financial flexibility to invest in commercial expansion, clinical studies and regulatory processes. Strong cash conversion reduces refinancing risk and supports durable capital allocation toward growth initiatives.
Bears Say
Regulatory Timing Uncertainty For CERAMENT VReclassification to a De Novo pathway extends approval timing and creates structural execution risk for a high‑potential product. Delays compress near‑term revenue upside and force the company to rely on existing SKUs for growth, making medium‑term forecasts contingent on regulatory milestones rather than only commercial execution.
Rising Commercial & Distributor CostsMaterial increases in commissions, distributor fees and S&M investment indicate a structurally higher cost of scaling into new geographies and accounts. If customer acquisition or usage per account lags expectations, elevated commercial cost structure could pressure operating leverage and compress sustainable margins.
Market Access Headwinds And Slow Clinical Adoption In New SegmentsRegulatory and hospital protocol changes in Germany and the early, evidence‑dependent adoption in spine/revision arthroplasty create persistent access risk. Structural reimbursement or protocol shifts and the need for additional clinical data can slow conversion from accounts to routine use, limiting near‑term penetration.
BONESUPPORT HOLDING AB News
BONEX FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was kr165.00 and its highest was kr346.40 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is kr14.11B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Apr 22, 2026 which is in 17 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Feb 24, 2026. The company reported kr0.665 earnings per share for the quarter, missing the consensus estimate of kr0.875 by -kr0.21.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.98.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of kr0.665 in its last earnings report, missing expectations of kr0.875. Following the earnings report the stock price went up 3.65%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in SE:BONEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
BONEX Company Deck
BONEX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: strong underlying sales growth (especially CERAMENT G in the U.S.), high gross margins, solid adjusted profitability and cash generation, plus continued geographic and product expansion (spine launch, De Novo path for CERAMENT V). Offsetting risks include currency translation headwinds that depressed reported growth, headwinds in Germany, rising commercial costs and distributor fees, newly introduced U.S. tariffs, and regulatory timing/uncertainty around CERAMENT V. Early-stage adoption in many newly opened accounts is still developing and some segments (spine, revision arthroplasty) require more evidence. Overall, the positives materially outweigh the challenges, with the company signaling confidence in 2026 constant-currency growth guidance (at least ~35%).View all SE:BONEX earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---